SCHEMBL31268916

SCHEMBL31268916

CC1(Oc2ncnc3c2nc(-c2ccc(OCCN4CCN(S(=O)(=O)O)CC4)cc2Cl)n3Cc2cc(Cl)ccn2)CC1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 5/20 0.34
▸ HRH4 Q9H3N8 3/20 0.33
▸ THRB P10828 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ PIK3CD O00329 1/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ESR1 P03372 4/20 0.32
▸ ESR2 Q92731 4/20 0.32
▸ KMT2A Q03164 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ CNR1 P21554 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269269 0.88 DRD2 (0.33) DRD2HRH4PIK3CDESR1ESR2
SCHEMBL30984048 0.88 PDE2A (0.38) DRD2HRH4KDM4EALDH1A1CNR1
SCHEMBL30983856 0.87 CNR1 (0.41) PIK3CDCNR1
SCHEMBL30983550 0.86 PDK2 (0.37) DRD2HRH4KDM4EPIK3CDCNR1
SCHEMBL31269351 0.86 PIK3CD (0.35) HRH4PIK3CDCNR1KCNH2
SCHEMBL31269005 0.85 PDE2A (0.35) HRH4PIK3CDCNR1KCNH2
SCHEMBL31268792 0.85 HRH4 (0.35) HRH4PIK3CDCNR1KCNH2
SCHEMBL31269116 0.85 ESR1 (0.38) DRD2HRH4KDM4EESR1ESR2
SCHEMBL31269218 0.85 THRB (0.38) HRH4THRBKDM4EALDH1A1PIK3CD
SCHEMBL30983885 0.84 CNR1 (0.33) HRH4PIK3CDCNR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback